Developer docs
API playgroundTry for free, no card

Search company profiles

Polymedco

Full company profile

uuid000csz5

Namestring
Polymedco
Legal namestring
Polymedco
Websiteurl
polymedco.com
Company typeenum
Private
Founded yearint
1980
Descriptiontext

Polymedco is a US-based medical device company founded in 1980 and headquartered in Cortlandt Manor, New York, that develops and commercializes clinical diagnostic test kits for the early detection of life-threatening diseases. The company primarily serves healthcare systems, hospitals, integrated delivery networks, reference laboratories, payors, and emergency departments with two principal product franchises: OC-Auto FIT, an automated fecal immunochemical testing (FIT) platform for colorectal cancer screening, and PATHFAST, a point-of-care cardiac biomarker analyzer. Complementing these are OC-Light S FIT (a qualitative strip test), SEDITEN and SEDIMAT ESR readers, and BTA stat for bladder cancer detection. Polymedco is positioned as the #1 automated noninvasive CRC screening tool globally with a Tier 1 US Preventive Services Task Force guideline recommendation, supported by published outcomes including a 43.8% increase in patient compliance, 25.5% reduction in CRC incidence, and 52.4% reduction in cancer mortality in community-based populations.

Short descriptiontext

Polymedco is a US-based medical device company founded in 1980 that develops clinical diagnostic test kits for early detection of colorectal cancer and cardiac events, serving healthcare systems, reference laboratories, and emergency departments with its OC-Auto FIT and PATHFAST analyzer platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCortlandt Manor, United States
HQ citystring
Cortlandt Manor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical diagnostic test kits, colorectal cancer screening, cardiac biomarker analyzers, point-of-care diagnostics, automated fecal immunochemical testing
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
In Vitro Clinical Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Diagnostic Equipment Sales
TypeHardware Sales
Description

Sale of diagnostic analyzers including OC-Auto FIT instruments (Sensor io and Sensor Diana) and PATHFAST benchtop analyzers for clinical laboratory and point-of-care settings.

polymedco.com
2Diagnostic Reagents and Consumables
TypeSubscription Recurring
Description

Recurring revenue from sale of test reagents, sample collection devices, and consumables for FIT screening and cardiac biomarker testing on proprietary analyzer platforms.

polymedco.com
3Programmatic Services
TypeProfessional Services
Description

Customizable programmatic solutions including patient education materials, in-service training, business reviews, and direct-to-patient mailing services to support screening program implementation.

polymedco.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1OC-Auto® FIT
Description

Automated fecal immunochemical test (FIT) for colorectal cancer screening - the #1 automated noninvasive CRC screening tool in the world with Tier 1 guideline recommendation

polymedco.com
+5 more records
Core offering1 text field

Polymedco develops, manufactures, and sells clinical diagnostic test kits and analyzers focused on early detection of life-threatening diseases. Its core offerings are the OC-Auto FIT family of automated fecal immunochemical testing analyzers and the OC-Light S FIT strip test for colorectal cancer screening, the PATHFAST benchtop analyzer and hs-cTnI-II assay for point-of-care cardiac biomarker testing, plus ESR readers (SEDITEN, SEDIMAT 15 Plus) and the BTA stat bladder cancer test. The company bundles these products with customizable programmatic screening services including training, patient education, and direct-to-patient outreach for healthcare systems, payors, providers, reference labs, and emergency departments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 43.8% increase in patient compliance with CRC screening
+7 more records
Product overview1 text field

Polymedco offers a portfolio of diagnostic products focused on early detection of life-threatening diseases, primarily in cancer screening and cardiac biomarker testing. The core product lines include OC-Auto® FIT (automated fecal immunochemical test for colorectal cancer screening) with associated analyzers (OC-Auto Sensor io and OC-Auto Sensor Diana), OC-Light S® FIT (qualitative strip test), and the PATHFAST® Analyzer system for cardiac biomarker testing including the FDA-cleared hs-cTnI-II high-sensitivity troponin test. Additional products include SEDITEN® and SEDIMAT® ESR Readers for erythrocyte sedimentation rate testing, and the BTA stat® Test for bladder cancer detection. The company provides customizable programmatic screening solutions to help health systems increase patient participation and reduce mortality rates.

Product and service1 record
1OC-Auto FIT
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1CancerX
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Polymedco joined CancerX in January 2024, a national oncology innovation initiative aimed at accelerating innovation in cancer detection and diagnosis. Participation in this partnership demonstrates commitment to advancing cancer screening technology and contributing to national screening improvement goals.

polymedco.com
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for Polymedco products in Argentina, responsible for local sales, distribution, and customer support of OC-Auto FIT and PATHFAST diagnostic solutions.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner covering Bolivia, Paraguay, and Uruguay markets for Polymedco diagnostic products including colorectal cancer screening and cardiac biomarker solutions.

4Ubuntu Med, Ldta. (Brazil)
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive or authorized distribution partner for Polymedco products in Brazil, handling local market penetration and customer relationships for diagnostic testing solutions.

polymedco.com
5Biocant Ldta. (Chile)
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Polymedco diagnostic products in Chile, supporting local healthcare providers with access to CRC screening and cardiac biomarker testing solutions.

polymedco.com
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Regional distribution partner covering Costa Rica, El Salvador, Guatemala, and Panama, providing comprehensive distribution services for Polymedco product portfolio.

Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Dual distribution partners in Mexico market, with Edomedica and MedPrimex providing local sales and distribution coverage for Polymedco diagnostic solutions.

8DIVCOM Labimed S.A. (Peru)
Strategic tierStandardTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Polymedco products in Peru, facilitating market access and distribution of screening and diagnostic testing solutions to local healthcare institutions.

polymedco.com
9Union for International Cancer Control (UICC) / BBC StoryWorks
Strategic tierFlagshipTypeGTM or Marketing Partner
Description

Polymedco collaborated with UICC and BBC StoryWorks Commercial Productions on the Rewriting Cancer series, producing a documentary featuring patient story and clinical expert perspectives on OC-Auto FIT screening, contributing to public health awareness and brand positioning.

polymedco.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Roche Diagnostics operates the Elecsys hs-cTn and cobas cardiac biomarker platforms, directly competing with PATHFAST in hospital labs. As the global IVD leader, Roche also competes with Polymedco for central lab automation footprint and CRC screening contract wins.

TypeDirect peer
Description

Guardant Health's Shield blood-based CRC screening test is a direct emerging competitor to OC-Auto FIT for noninvasive CRC screening. Both companies compete for USPSTF inclusion, Medicare coverage, and health system population health contracts.

TypeBroad incumbent
Description

Hologic's diagnostics division focuses on women's health, molecular, and cytology screening, including HPV and STI testing sold to similar healthcare system customers that buy OC-Auto FIT and PATHFAST. While not a direct FIT competitor, Hologic competes for the same hospital and reference lab IVD contracts.

4Eiken Chemical
TypeOthers
Description

Eiken Chemical is the originator of the OC-Auto FIT latex agglutination fecal immunochemical test technology and is the manufacturer of the analyzers Polymedco distributes. The relationship is a technology/licensing partnership rather than direct competition in Polymedco's licensed markets.

TypeDirect peer
Description

Sekisui Diagnostics manufactures fecal immunochemical and occult blood tests for CRC screening, directly competing with OC-Auto FIT and OC-Light S in clinical labs and screening programs. Both companies target the same FIT-based screening market with similar automated analyzer platforms.

TypeDirect peer
Description

Exact Sciences markets Cologuard, the most established non-colonoscopy CRC screening test in the US, competing head-to-head with Polymedco's OC-Auto FIT for screening share. Both companies target the same patient population, payors, and healthcare systems for noninvasive CRC screening.

7Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter is a major IVD incumbent whose Access family of hs-cTnI assays and DxH hematology analyzers compete with PATHFAST cardiac menu and Polymedco's ESR (SEDITEN/SEDIMAT) lines. The company serves the same hospital and reference lab customers as Polymedco.

TypeBroad incumbent
Description

Siemens Healthineers markets the Atellica and ADVIA Centaur cardiac biomarker platforms that compete with PATHFAST in hospital core labs. As a broad IVD incumbent with established enterprise health system contracts, Siemens competes with Polymedco for the same hospital, payor, and reference lab relationships.

TypeDirect peer
Description

QuidelOrtho markets the Triage family of rapid cardiac biomarker tests used in emergency settings, directly competing with PATHFAST for near-patient troponin and BNP testing. Both companies focus on rapid immunoassays and point-of-care diagnostics.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's i-STAT and ARCHITECT platforms provide point-of-care and central lab cardiac biomarker testing, directly competing with PATHFAST in emergency and STAT lab settings. Abbott is a broadly diversified IVD incumbent spanning cardiac, infectious disease, and core lab diagnostics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polymedco

In Vitro Clinical Diagnosticspolymedco.com

Polymedco is a US-based medical device company founded in 1980 that develops clinical diagnostic test kits for early detection of colorectal cancer and cardiac events, serving healthcare systems, reference laboratories, and emergency departments with its OC-Auto FIT and PATHFAST analyzer platforms.

What Polymedco does

Polymedco is a US-based medical device company founded in 1980 and headquartered in Cortlandt Manor, New York, that develops and commercializes clinical diagnostic test kits for the early detection of life-threatening diseases. The company primarily serves healthcare systems, hospitals, integrated delivery networks, reference laboratories, payors, and emergency departments with two principal product franchises: OC-Auto FIT, an automated fecal immunochemical testing (FIT) platform for colorectal cancer screening, and PATHFAST, a point-of-care cardiac biomarker analyzer. Complementing these are OC-Light S FIT (a qualitative strip test), SEDITEN and SEDIMAT ESR readers, and BTA stat for bladder cancer detection. Polymedco is positioned as the #1 automated noninvasive CRC screening tool globally with a Tier 1 US Preventive Services Task Force guideline recommendation, supported by published outcomes including a 43.8% increase in patient compliance, 25.5% reduction in CRC incidence, and 52.4% reduction in cancer mortality in community-based populations.

Polymedco firmographics

Firmographics
Name
Polymedco
Legal name
Polymedco
Website
https://polymedco.com
Company type
Private
Founded year
1980
Operating status
Operating
Headcount range
101–250 employees
Short description
Polymedco is a US-based medical device company founded in 1980 that develops clinical diagnostic test kits for early detection of colorectal cancer and cardiac events, serving healthcare systems, reference laboratories, and emergency departments with its OC-Auto FIT and PATHFAST analyzer platforms.
Ownership category
akta.pro rank

Polymedco industry classification

Industry
Product category
In Vitro Clinical Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Clinical diagnostic test kits
  • Colorectal cancer screening
  • Cardiac biomarker analyzers
  • Point-of-care diagnostics
  • Automated fecal immunochemical testing

Where Polymedco is headquartered

Location

Headquarters

HQ city
Cortlandt Manor
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Polymedco business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Medical Diagnostic Equipment Sales: Sale of diagnostic analyzers including OC-Auto FIT instruments (Sensor io and Sensor Diana) and PATHFAST benchtop analyzers for clinical laboratory and point-of-care settings.
  2. Diagnostic Reagents and Consumables: Recurring revenue from sale of test reagents, sample collection devices, and consumables for FIT screening and cardiac biomarker testing on proprietary analyzer platforms.
  3. Programmatic Services: Customizable programmatic solutions including patient education materials, in-service training, business reviews, and direct-to-patient mailing services to support screening program implementation.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Polymedco product offering

Product offering

Core offering

Polymedco develops, manufactures, and sells clinical diagnostic test kits and analyzers focused on early detection of life-threatening diseases. Its core offerings are the OC-Auto FIT family of automated fecal immunochemical testing analyzers and the OC-Light S FIT strip test for colorectal cancer screening, the PATHFAST benchtop analyzer and hs-cTnI-II assay for point-of-care cardiac biomarker testing, plus ESR readers (SEDITEN, SEDIMAT 15 Plus) and the BTA stat bladder cancer test. The company bundles these products with customizable programmatic screening services including training, patient education, and direct-to-patient outreach for healthcare systems, payors, providers, reference labs, and emergency departments.

Product overview

Polymedco offers a portfolio of diagnostic products focused on early detection of life-threatening diseases, primarily in cancer screening and cardiac biomarker testing. The core product lines include OC-Auto® FIT (automated fecal immunochemical test for colorectal cancer screening) with associated analyzers (OC-Auto Sensor io and OC-Auto Sensor Diana), OC-Light S® FIT (qualitative strip test), and the PATHFAST® Analyzer system for cardiac biomarker testing including the FDA-cleared hs-cTnI-II high-sensitivity troponin test. Additional products include SEDITEN® and SEDIMAT® ESR Readers for erythrocyte sedimentation rate testing, and the BTA stat® Test for bladder cancer detection. The company provides customizable programmatic screening solutions to help health systems increase patient participation and reduce mortality rates.

Differentiator

Problem solved

Functional benefit

Brands

  • OC-Auto® FIT: Automated fecal immunochemical test (FIT) for colorectal cancer screening - the #1 automated noninvasive CRC screening tool in the world with Tier 1 guideline recommendation
  • PATHFAST®
  • OC-Light S® FIT
  • SEDITEN® ESR Reader
  • SEDIMAT® 15 Plus
  • BTA stat® Test

Products and services

  • OC-Auto FIT

Quantifiable outcome

  • 43.8% increase in patient compliance with CRC screening
  • +7 more outcomes

Companies that use Polymedco

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Polymedco technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Polymedco partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered strategic, standard and flagship.

  • CancerXstrategicStrategic or Co-development Partner · 30 January 2024Polymedco joined CancerX in January 2024, a national oncology innovation initiative aimed at accelerating innovation in cancer detection and diagnosis. Participation in this partnership demonstrates commitment to advancing cancer screening technology and contributing to national screening improvement goals.
  • Bio Analytica S.A. (Argentina)standardChannel Partner/ Reseller/ DistributorInternational distribution partner for Polymedco products in Argentina, responsible for local sales, distribution, and customer support of OC-Auto FIT and PATHFAST diagnostic solutions.
  • Labimed S.A. (Bolivia, Paraguay, Uruguay)standardChannel Partner/ Reseller/ DistributorDistribution partner covering Bolivia, Paraguay, and Uruguay markets for Polymedco diagnostic products including colorectal cancer screening and cardiac biomarker solutions.
  • Ubuntu Med, Ldta. (Brazil)standardChannel Partner/ Reseller/ DistributorExclusive or authorized distribution partner for Polymedco products in Brazil, handling local market penetration and customer relationships for diagnostic testing solutions.
  • Biocant Ldta. (Chile)standardChannel Partner/ Reseller/ DistributorAuthorized distributor for Polymedco diagnostic products in Chile, supporting local healthcare providers with access to CRC screening and cardiac biomarker testing solutions.
  • Capris Médica (Costa Rica, El Salvador, Guatemala, Panama)standardChannel Partner/ Reseller/ DistributorRegional distribution partner covering Costa Rica, El Salvador, Guatemala, and Panama, providing comprehensive distribution services for Polymedco product portfolio.
  • Edomedica S.A. de C.V. and MedPrimex LLC (Mexico)standardChannel Partner/ Reseller/ DistributorDual distribution partners in Mexico market, with Edomedica and MedPrimex providing local sales and distribution coverage for Polymedco diagnostic solutions.
  • DIVCOM Labimed S.A. (Peru)standardChannel Partner/ Reseller/ DistributorAuthorized distributor for Polymedco products in Peru, facilitating market access and distribution of screening and diagnostic testing solutions to local healthcare institutions.
  • Union for International Cancer Control (UICC) / BBC StoryWorksflagshipGTM or Marketing PartnerPolymedco collaborated with UICC and BBC StoryWorks Commercial Productions on the Rewriting Cancer series, producing a documentary featuring patient story and clinical expert perspectives on OC-Auto FIT screening, contributing to public health awareness and brand positioning.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Polymedco competitors and assessment

Company assessment

Broad incumbents

  • Roche Diagnostics: Roche Diagnostics operates the Elecsys hs-cTn and cobas cardiac biomarker platforms, directly competing with PATHFAST in hospital labs. As the global IVD leader, Roche also competes with Polymedco for central lab automation footprint and CRC screening contract wins.
  • Hologic: Hologic's diagnostics division focuses on women's health, molecular, and cytology screening, including HPV and STI testing sold to similar healthcare system customers that buy OC-Auto FIT and PATHFAST. While not a direct FIT competitor, Hologic competes for the same hospital and reference lab IVD contracts.
  • Beckman Coulter (Danaher): Beckman Coulter is a major IVD incumbent whose Access family of hs-cTnI assays and DxH hematology analyzers compete with PATHFAST cardiac menu and Polymedco's ESR (SEDITEN/SEDIMAT) lines. The company serves the same hospital and reference lab customers as Polymedco.
  • Siemens Healthineers: Siemens Healthineers markets the Atellica and ADVIA Centaur cardiac biomarker platforms that compete with PATHFAST in hospital core labs. As a broad IVD incumbent with established enterprise health system contracts, Siemens competes with Polymedco for the same hospital, payor, and reference lab relationships.
  • Abbott Diagnostics: Abbott's i-STAT and ARCHITECT platforms provide point-of-care and central lab cardiac biomarker testing, directly competing with PATHFAST in emergency and STAT lab settings. Abbott is a broadly diversified IVD incumbent spanning cardiac, infectious disease, and core lab diagnostics.

Direct peers

  • Guardant Health: Guardant Health's Shield blood-based CRC screening test is a direct emerging competitor to OC-Auto FIT for noninvasive CRC screening. Both companies compete for USPSTF inclusion, Medicare coverage, and health system population health contracts.
  • Sekisui Diagnostics: Sekisui Diagnostics manufactures fecal immunochemical and occult blood tests for CRC screening, directly competing with OC-Auto FIT and OC-Light S in clinical labs and screening programs. Both companies target the same FIT-based screening market with similar automated analyzer platforms.
  • Exact Sciences: Exact Sciences markets Cologuard, the most established non-colonoscopy CRC screening test in the US, competing head-to-head with Polymedco's OC-Auto FIT for screening share. Both companies target the same patient population, payors, and healthcare systems for noninvasive CRC screening.
  • QuidelOrtho: QuidelOrtho markets the Triage family of rapid cardiac biomarker tests used in emergency settings, directly competing with PATHFAST for near-patient troponin and BNP testing. Both companies focus on rapid immunoassays and point-of-care diagnostics.

Others

  • Eiken Chemical: Eiken Chemical is the originator of the OC-Auto FIT latex agglutination fecal immunochemical test technology and is the manufacturer of the analyzers Polymedco distributes. The relationship is a technology/licensing partnership rather than direct competition in Polymedco's licensed markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Polymedco social profiles

Digital presence

Polymedco financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polymedco leadership team

Management profile

Number of profiles

Profiles8 records

Polymedco funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polymedco M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polymedco

What does Polymedco do?

Polymedco develops, manufactures, and sells clinical diagnostic test kits and analyzers focused on early detection of life-threatening diseases. Its core offerings are the OC-Auto FIT family of automated fecal immunochemical testing analyzers and the OC-Light S FIT strip test for colorectal cancer screening, the PATHFAST benchtop analyzer and hs-cTnI-II assay for point-of-care cardiac biomarker testing, plus ESR readers (SEDITEN, SEDIMAT 15 Plus) and the BTA stat bladder cancer test. The company bundles these products with customizable programmatic screening services including training, patient education, and direct-to-patient outreach for healthcare systems, payors, providers, reference labs, and emergency departments.

Is Polymedco a public or private company?

Polymedco is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Polymedco founded?

Polymedco was founded in 1980. It employs 101 to 250 people.

Where is Polymedco based?

Polymedco is headquartered in Cortlandt Manor, United States, in the North America region.

How does Polymedco make money?

Three revenue lines are on record. Medical Diagnostic Equipment Sales are the primary driver. The others are diagnostic Reagents and Consumables and programmatic Services.

Who are Polymedco's main competitors?

Broad incumbents on record are Roche Diagnostics, Hologic, Beckman Coulter (Danaher), Siemens Healthineers and Abbott Diagnostics. Direct peers are Guardant Health, Sekisui Diagnostics, Exact Sciences and QuidelOrtho. Eiken Chemical is listed as an others.

Does Polymedco have an API?

No public API is recorded for Polymedco.

What industry is Polymedco in?

Polymedco's product category is In Vitro Clinical Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPolymedco, LLC awarded National Group Purchasing Agreement with Premier, Inc.Polymedco, LLC was awarded a national group purchasing agreement with Premier, Inc., effective November 1, 2026. The agreement allows Premier members to access special pricing and terms for the PATHFAST point-of-care analyzer and cardiac biomarker testing menu. Polymedco's CEO said the deal will expand access to the analyzer across Premier's member health systems.FinancialContent Business PagePolymedco, LLC awarded National Group Purchasing Agreement with Premier, Inc.Polymedco, LLC was awarded a national group purchasing agreement with Premier, Inc., effective November 1, 2026. The agreement allows Premier members to access special pricing and terms for the PATHFAST point-of-care analyzer and cardiac biomarker testing menu. Polymedco CEO Chris Mathews said the deal will expand access to the analyzer across Premier's member health systems.openPR.comColorectal Cancer Screening Market Growth in Future Scope 2025-2032 | Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex CorporationThe global colorectal cancer screening market is projected to grow from USD 16.57 billion in 2025 to USD 27.15 billion by 2032, a CAGR of 7.3%. The forecast period is 2025-2032, with key players including Polymedco, Eiken Chemical, and Sysmex.PR NewswirePolymedco announces US FDA clearance of the PATHFAST high-sensitivity cardiac troponin I (hs-cTnI-II) test as an aid in the diagnosis of myocardial infarctionPolymedco announced FDA 510(k) clearance for the PATHFAST high-sensitivity cardiac troponin I (hs-cTnI-II) test, making it the first and only hs-cTn test cleared for point-of-care use in the United States. The test delivers results in 17 minutes at the point of care compared to the typical hour or more required for central laboratory testing, enabling faster diagnosis of myocardial infarction in emergency departments. The clearance allows Polymedco to sell the test in the US for use on its PATHFAST analyzer with whole blood and plasma specimens, addressing over 7 million annual emergency department visits for chest pain.YahooPolymedco Joins CancerX to Accelerate Innovation in Cancer Detection and DiagnosisPolymedco joined CancerX, a public-private partnership under the White House Cancer Moonshot, to advance cancer detection and diagnosis. The company aims to expand affordable screening and early detection, with collaboration on advanced diagnostic tools.PR NewswireRoundTable Healthcare Partners invests in Polymedco alongside owner-FoundersRoundTable Healthcare Partners, a private equity firm, announced the completion of a majority investment into Polymedco, a diagnostic tests company. Polymedco, founded in 1980 and based in Cortlandt Manor, NY, specializes in colorectal cancer screening and cardiac condition diagnostics, with products distributed across North America. The investment represents RoundTable's sixth equity commitment from its $700 million Equity Fund V, with both parties expressing confidence in the partnership's growth potential.PR NewswirePolymedco CDP, LLC. Announces Updated American Cancer Society Guidelines for Colorectal Cancer ScreeningThe American Cancer Society lowered colorectal cancer screening start age from 50 to 45 for average-risk adults. Polymedco, a FIT testing provider, will assist in transitioning to screen younger patients. The update responds to increased incidence among younger individuals.PR NewswirePolymedco CDP, LLC. Announces New Agreement with L.A. County for Colorectal Cancer ScreeningLA County has awarded Polymedco CDP, LLC a 5-year contract starting March 2, 2017, continuing its use of Polymedco's OC-Auto and OC-Light fecal immunochemical test products for colorectal cancer screening of county residents. The previous five-year contract resulted in high testing volumes and increased patient screening, demonstrating the product's effectiveness in early cancer detection. Colorectal cancer has a 91% survival rate when caught in Stage I but only 11% when caught in Stage IV, underscoring the importance of screening programs.PR NewswireNewly issued USPSTF Guidelines for Colorectal Cancer include complete line of products from PolymedcoThe United States Preventive Services Task Force (USPSTF) released new colorectal cancer screening guidelines on June 21, 2016, classifying Polymedco's OC-Auto FIT product family and the Epi proColon blood test as Grade A recommended screening tests for adults aged 50 to 75. The guidelines identified Polymedco's OC-Auto products as having the best test performance characteristics among available options. Polymedco stated it expects the new guidelines to drive higher screening rates and supports the goal of achieving 80% population screening for colorectal cancer by 2018.